Depending on the type of ICIs, immunohistochemistry expression of PD-L1/PD-1 on tumor cells and immune cells and tumor mutation burden (TMB) have emerged as promising biomarkers for predicting response to immunotherapy. This evidence concerns the gene CD274 and neoplasm.